Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study
Background: In 2014, Ontario augmented its publicly funded multiple-marker screening
program for prenatal aneuploidy by incorporating cell-free fetal DNA (cffDNA) analysis for …
program for prenatal aneuploidy by incorporating cell-free fetal DNA (cffDNA) analysis for …
A 2‐year review of publicly funded cell‐free DNA screening in Ontario: utilization and adherence to funding criteria
K Bellai‐Dussault, L Meng, T Huang… - Prenatal …, 2020 - Wiley Online Library
Objective Ontario offers a publicly funded modified contingent model of prenatal screening
for aneuploidy in which cell‐free DNA (cfDNA) screening is covered for pregnancies at …
for aneuploidy in which cell‐free DNA (cfDNA) screening is covered for pregnancies at …
Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age
Objective: To determine how adults in the United States view non-invasive prenatal testing
using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake. Study Design: A …
using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake. Study Design: A …
Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada
SD Dougan, N Okun, K Bellai-Dussault, L Meng… - CMAJ, 2021 - Can Med Assoc
BACKGROUND: The emergence of cell-free fetal DNA (cfDNA) testing technology has
disrupted the landscape of prenatal screening for trisomies 21 (T21) and 18 (T18). Publicly …
disrupted the landscape of prenatal screening for trisomies 21 (T21) and 18 (T18). Publicly …
[HTML][HTML] Impact of cell-free fetal DNA screening on patients' choice of invasive procedures after a positive California prenatal screen result
FT Shah, K Steinhaus French, KE Osann… - Journal of clinical …, 2014 - mdpi.com
Until recently, maternal serum analyte levels paired with sonographic fetal nuchal
translucency measurement was the most accurate prenatal screen available for Trisomies …
translucency measurement was the most accurate prenatal screen available for Trisomies …
250: Disparities in cell free fetal DNA aneuploidy screening uptake in an urban safety net hospital
C Smith-Lin, C Wang, A Hanchate, P Connors… - American Journal of …, 2018 - ajog.org
Objective To identify racial disparities in cell free fetal DNA (cffDNA) first-line aneuploidy
screening use among advanced maternal age women at a safety net hospital. Study Design …
screening use among advanced maternal age women at a safety net hospital. Study Design …
Racial and ethnic differences in uptake of cell‐free fetal DNA aneuploidy screening in an urban safety net hospital
CD Yarrington, C Smith‐Lin, R Neuhalfen… - Prenatal …, 2021 - Wiley Online Library
Objective To identify racial disparities in cell‐free fetal DNA (cffDNA) first‐line aneuploidy
screening use among advanced maternal age women at a safety net hospital. Study Design …
screening use among advanced maternal age women at a safety net hospital. Study Design …
Noninvasive testing for fetal aneuploidy: a Hong Kong perspective
DS Sahota - AJOB Empirical Bioethics, 2015 - Taylor & Francis
The discovery that cell-free fetal DNA (cffDNA) is detectable in maternal blood has led to the
creation and development of a multi-million-dollar for-profit industry, predominantly focused …
creation and development of a multi-million-dollar for-profit industry, predominantly focused …
[HTML][HTML] The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population
GE Palomaki, EM Kloza, BM O'Brien, EE Eklund… - Genetics in …, 2017 - nature.com
Objective: To assess the clinical utility of cell-free DNA (cfDNA)-based screening for
aneuploidies offered through primary obstetrical care providers to a general pregnancy …
aneuploidies offered through primary obstetrical care providers to a general pregnancy …
Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations
Purpose Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has
been commercially available in the United States since 2011. In 2016, the American College …
been commercially available in the United States since 2011. In 2016, the American College …